EUROPEAN COMMISSION

Brussels, 22.4.2026
C(2026) 2795 final

PUBLIC VERSION

Charlesbank Capital Partners LLC
200 Clarendon Street, 54th Floor
Boston, MA 02116
United States

Nordic Capital IX Limited
Aztec Group House, IFC6
The Esplanade
St. Helier, JE4 0QH
Jersey

Subject: **Case M.12319 – CHARLESBANK / NORDIC CAPITAL / TECOMET / ORCHID**
Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004 ([1]) and Article 57 of the Agreement on the European Economic Area ([2])

Dear Sir or Madam,

(1) On 25 March 2026, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation, by which Charlesbank Capital Partners, LLC ("Charlesbank", United States), and Nordic Capital IX Limited ("Nordic Capital", Jersey), belonging to the Nordic Capital group of funds and vehicles (Jersey) will acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of a newly created joint venture (the "JV"), comprising both Tecomet, Inc. ("Tecomet", United States), currently controlled by Charlesbank, and Orchid MPS Holdings, LLC ("Orchid", United States), currently controlled by Nordic Capital, by way of purchase of shares. ([3])

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. The terminology of the TFEU will be used throughout this decision.
([2]) OJ L 1, 3.1.1994, p. 3 (the 'EEA Agreement').
([3]) OJ C, C/2026/2079, 7.4.2026.

(2) The business activities of the undertakings concerned are the following:

– Charlesbank is a US private equity firm investing in Business & Consumer Services, Healthcare, Industrial, and Technology. Its subsidiary Tecomet is global contract manufacturing organisation ("CMO") focusing on med-tech (principally orthopaedic) implants, instruments, and cases and trays,

– Nordic Capital is a private equity firm which invests in large and medium sized companies active in a wide range of sectors including healthcare, technology and payments, financial services, and to a lesser extent, consumer and industrial and business services within the EEA and globally. Its subsidiary Orchid is a global CMO focusing on orthopaedic implants and instruments.

(3) The JV will be active in CMO services for orthopaedic implants and instruments.

(4) After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraph 5(d) of the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004. ([4])

(5) For the reasons set out in the Notice on a simplified treatment, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.

For the Commission

(Signed)
Anthony WHELAN
Director-General
Directorate-General for Competition

([4]) OJ C 160, 5.5.2023, p. 1 (the 'Notice on a simplified treatment').